Oppenheimer set a $10.00 price target on Mesoblast (NASDAQ:MESO) in a report issued on Tuesday, TipRanks reports. The firm currently has a buy rating on the stock.
Several other research analysts have also commented on MESO. ValuEngine upgraded shares of Mesoblast from a hold rating to a buy rating in a report on Tuesday. HC Wainwright set a $7.00 price objective on shares of Mesoblast and gave the stock a buy rating in a research note on Friday, August 30th. Zacks Investment Research lowered shares of Mesoblast from a buy rating to a hold rating in a research report on Friday, September 6th. Maxim Group reissued a buy rating and issued a $16.00 target price on shares of Mesoblast in a research note on Wednesday, June 12th. Finally, Chardan Capital set a $6.00 target price on shares of Mesoblast and gave the company a hold rating in a report on Friday, August 30th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has an average rating of Buy and a consensus target price of $11.25.
Shares of Mesoblast stock traded up $0.46 during trading hours on Tuesday, reaching $6.54. The stock had a trading volume of 239,711 shares, compared to its average volume of 48,602. The firm has a 50 day simple moving average of $5.06 and a two-hundred day simple moving average of $5.09. The firm has a market capitalization of $473.68 million, a price-to-earnings ratio of -7.19 and a beta of 1.77. The company has a current ratio of 1.41, a quick ratio of 1.92 and a debt-to-equity ratio of 0.14. Mesoblast has a 1 year low of $3.35 and a 1 year high of $8.78.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley boosted its holdings in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 147,702 shares of the company’s stock after buying an additional 109,295 shares during the period. Morgan Stanley owned about 0.16% of Mesoblast worth $784,000 as of its most recent SEC filing. Institutional investors own 2.76% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Recommended Story: What is Depreciation?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.